UNSPSC 51432202: Dihydralazine

This classification denotes an antihypertensive agent and hydrazine with the molecular formula C8H10N6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PCU411F5L6, chemically known as 2,3-dihydro-1,4-phthalazinedione dihydrazone but generally known as dihydralazine, which bears US NIH Compound Identifier 10230. European Medicines Agency schedules Dihydralazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07137MIG.

UNSPSC 51432202 Dihydralazine is a Commodity code covering pharmaceutical active ingredients and finished medications procured by state and local public health systems, primarily fire rescue services and state health agencies. State and local buyers under this code source advanced life support medications, generic multi-source pharmaceuticals, and over-the-counter products through sealed-bid procurements, cooperative purchasing agreements, and exploratory market-intelligence solicitations. Issuing bodies include municipal fire rescue departments (City of Tampa), state health commissions (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The scope of work covers supply of specific medication line items with firm pricing, FDA compliance, cGMP and Drug Supply Chain Security Act certification, comprehensive product documentation including Safety Data Sheets and National Drug Codes, expiration-date guarantees of six months to nine months minimum remaining shelf life, and logistics support including delivery within ten calendar days of order and replacement of expired stock before expiration.

Recent activity spans Texas, Minnesota, Oregon, and Florida. The City of Tampa's Purchasing Department issued an IFB (Solicitation 26P00188) for Advanced Life Support Medications for Tampa Fire Rescue on April 24, 2026, with a response deadline of April 8, 2026, seeking 370 units of Labetalol HCI, 1,810 units of Epinephrine, 330 units of Adenosine, and 1,020 units of Diltiazem at an estimated contract value of $40,000.00, with a small local business enterprise sheltered-market designation offering a five percent bid discount. The Minnesota Department of Administration issued an RFP through MMCAP (Solicitation S1070000015802) for generic multi-source pharmaceuticals and OTC products due March 26, 2026, requiring vendors to supply through three authorized wholesalers with contract effectiveness July 1, 2026, and a two-year term. The Texas Health and Human Services Commission posted an RFI (HHS0017013) on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling early-stage procurement planning without identified budget or award values at this phase.